医学
药物开发
仿形(计算机编程)
临床前研究
药品
临床前试验
生物信息学
肿瘤科
癌症研究
计算生物学
药理学
医学物理学
计算机科学
生物
操作系统
作者
Luca Pompili,Manuela Porru,Carla Caruso,Annamaria Biroccio,Carlo Leonetti
标识
DOI:10.1186/s13046-016-0462-4
摘要
Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the 'right' treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI